By Fineline Cube 
Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).
BC006 Development and Indications
BC006 is a humanized IgG1 mAb targeting macrophage CSF-1R and is under development for advanced malignancies, hematologic tumors, and bone/joint disorders. The drug initially secured Chinese clinical trial authorization in March 2021. This latest approval expands its clinical evaluation into IPF, a progressive lung disease with significant unmet medical needs.-Fineline Info & Tech